Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Bosisio, FM; Cerroni, L.
Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Am J Dermatopathol. 2015; 37(2):115-121
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Cerroni Lorenzo
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
T-follicular helper (Tfh) lymphocytes represent the neoplastic cells of angioimmunoblastic T-cell lymphoma and have been observed also in several cutaneous T-cell lymphomas (CTCLs) and extracutaneous T-cell lymphomas, including peripheral T-cell lymphoma, not otherwise specified, mycosis fungoides (MF), cutaneous CD4 small/medium T-cell lymphoma (CD4SMTCL), and Sezary syndrome. We studied a large number of different types of primary CTCL for expression of Tfh markers, including 36 biopsies from 21 patients with MF (with sequential biopsies from patch stage and tumor stage of 15 patients), 13 patients with CD4SMTCL, 9 with lymphomatoid papulosis, 11 with cutaneous anaplastic large cell lymphoma (cALCL), 2 with cutaneous γ/δ T-cell lymphoma, 8 with subcutaneous panniculitis-like T-cell lymphoma, 3 with cutaneous aggressive epidermotropic CD8 cytotoxic T-cell lymphoma, 6 with cutaneous peripheral T-cell lymphoma, not otherwise specified, and 1 with Sezary syndrome. Expression of at least 3 of 5 markers (PD-1, CXCL-13, ICOS, Bcl-6, and CD10) in >10% of tumor cells was observed in 33 biopsies (MF = 20; CD4SMTCL = 11; 1 each cutaneous anaplastic large cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma, respectively). Our study shows that a Tfh phenotype is very common in MF and CD4SMTCL but can be observed rarely also in other types of CTCL. Expression of Tfh markers should not be used for classification of any entity of CTCL and may only integrate other immunohistochemical stainings for a more accurate characterization of these disorders. Precise distinction of Tfh-positive CTCLs from secondary skin manifestations of angioimmunoblastic T-cell lymphoma cannot rest on demonstration of a Tfh phenotype alone and should be achieved by a synthesis of clinical, histological, and phenotypic features.
Find related publications in this database (using NLM MeSH Indexing)
Biomarkers, Tumor - analysis
Biopsy -
Disease Progression -
Humans -
Immunohistochemistry -
Immunophenotyping -
Leukemia, Lymphocytic, Chronic, B-Cell - immunology
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Lymphocytes, Tumor-Infiltrating - immunology
Lymphoma, Primary Cutaneous Anaplastic Large Cell - immunology
Lymphoma, Primary Cutaneous Anaplastic Large Cell - pathology
Lymphoma, T-Cell - immunology
Lymphoma, T-Cell - pathology
Lymphoma, T-Cell, Cutaneous - immunology
Lymphoma, T-Cell, Cutaneous - pathology
Mycosis Fungoides - immunology
Mycosis Fungoides - pathology
Neoplasm Staging -
Panniculitis - immunology
Panniculitis - pathology
Phenotype -
Predictive Value of Tests -
Sezary Syndrome - immunology
Sezary Syndrome - pathology
Skin Neoplasms - immunology
Skin Neoplasms - pathology
T-Lymphocytes, Helper-Inducer - immunology

Find related publications in this database (Keywords)
T-follicular helper lymphocytes
mycosis fungoides
cutaneous T-cell lymphoma
lymphomatoid papulosis
cutaneous anaplastic large cell lymphoma
subcutaneous panniculitis-like T-cell lymphoma
cutaneous CD4(+) small/medium T-cell lymphoma
cutaneous gamma/delta T-cell lymphoma
cutaneous aggressive epidermotropic CD8(+) cytotoxic T-cell lymphoma
cutaneous peripheral T-cell lymphoma
NOS
Sezary syndrome
© Meduni Graz Impressum